| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T4 |
0-197 |
Sentence |
denotes |
Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every country in the world. |
| T5 |
198-334 |
Sentence |
denotes |
Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacotherapies against this disease. |
| T6 |
335-444 |
Sentence |
denotes |
Because of this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. |
| T7 |
445-591 |
Sentence |
denotes |
Observed hypercoagulability in patients with COVID-19 has created debate within the critical care community on the therapeutic utility of heparin. |
| T8 |
592-786 |
Sentence |
denotes |
We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. |
| T9 |
787-988 |
Sentence |
denotes |
Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through antiviral and anti-inflammatory effects. |
| T10 |
989-1208 |
Sentence |
denotes |
Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. |
| T11 |
1209-1439 |
Sentence |
denotes |
Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy. |
